Go to content

Publications

378 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Appendix to guideline for cost-effectiveness models in R - packages and versions

    Appendix to guideline for cost-effectiveness models in R - packages and versions.

    Publication | 15-12-2022

  2. Guideline for building cost-effectiveness models in R

    Guideline for building cost-effectiveness models in R.

    Publication | 15-12-2022

  3. Package advice atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

    The National Health Care Institute advises the Minister to include atidarsagene autotemcel (Libmeldy®) in the basic health care ...

    Report | 27-09-2022

  4. Package advice brexucabtagene autoleucel (Tecartus®) refractory mantle cell lymphoma

    The National Health Care Institute advises the Minister not to include brexucabtagene autoleucel (Tecartus®) in the basic health ...

    Report | 09-09-2022

  5. Package advice sacituzumab govitecan (Trodelvy®) for the treatment of inoperable or metastasized triple-negative breast cancer

    The National Health Care Institute advises the Minister to include sacituzumab govitecan (Trodelvy®) in the basic health care ...

    Report | 29-07-2022

  6. GVS advice testosterone undecanoate (Nebido®)

    The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...

    Report | 21-07-2022

  7. Package advice risdiplam (Evrysdi®) for the treatment of 5q spinal muscular atrophy (SMA)

    The National Health Care Institute advises the Minister to include risdiplam (Evrysdi®) in the health insurance package for the ...

    Report | 15-07-2022

  8. GVS advice setmelanotide (Imcivree®)

    The National Health Care Institute advises the Minister to include setmelanotide (Imcivree®) in List 1B of the GVS. Setmelanotide ...

    Report | 08-07-2022

  9. GVS advice metreleptin (Myalepta®)

    The National Health Care Institute advises the Minister to include metreleptin (Myalepta®) in List 1B of the GVS. Metreleptin is ...

    Report | 08-07-2022

  10. Position of the National Health Care Institute on nivolumab (Opdivo®) for the treatment of dMMR- of MSI tumors

    The National Health Care Institute concludes that nivolumab (Opdivo®) for the treatment of certain patients with locally advanced ...

    Report | 23-06-2022

Go to